{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:10:28Z","timestamp":1792019428614,"version":"4.4.0"},"reference-count":37,"publisher":"Massachusetts Medical Society","issue":"19","license":[{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.nejmgroup.org\/legal\/terms-of-use.htm"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["N Engl J Med"],"published-print":{"date-parts":[[2025,11,13]]},"DOI":"10.1056\/nejmoa2511734","type":"journal-article","created":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T06:30:19Z","timestamp":1760855419000},"page":"1912-1925","source":"Crossref","is-referenced-by-count":104,"title":["Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer"],"prefix":"10.1056","volume":"393","author":[{"given":"Javier","family":"Cort\u00e9s","sequence":"first","affiliation":[{"name":"International Breast Cancer Center, Pangaea Oncology, Quiron Group, Barcelona"},{"name":"IOB Madrid, Institute of Oncology, Hospital Beata Mar\u00eda Ana, Madrid"},{"name":"Oncology Department, Hospital Universitario Torrej\u00f3n, Ribera Salud Group, Madrid"},{"name":"Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid"},{"name":"Medica Scientia Innovation Research, Barcelona"},{"name":"Medica Scientia Innovation Research, Ridgewood, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Punie","sequence":"additional","affiliation":[{"name":"Medical Oncology, Oncology Center Antwerp, Ziekenhuis aan de Stroom, Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Barrios","sequence":"additional","affiliation":[{"name":"Latin American Cooperative Oncology Group, Porto Alegre, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara A.","family":"Hurvitz","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington Medicine, Clinical Research Division, Fred Hutchinson Cancer Center, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Schneeweiss","sequence":"additional","affiliation":[{"name":"Heidelberg University Hospital, Heidelberg, Germany"},{"name":"German Cancer Research Center, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2303-2764","authenticated-orcid":false,"given":"Joohyuk","family":"Sohn","sequence":"additional","affiliation":[{"name":"Yonsei Cancer Center, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriko","family":"Tokunaga","sequence":"additional","affiliation":[{"name":"National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Brufsky","sequence":"additional","affiliation":[{"name":"Hillman Cancer Center, Magee-Womens Hospital, University of Pittsburgh Medical Center, Pittsburgh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeon Hee","family":"Park","sequence":"additional","affiliation":[{"name":"Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binghe","family":"Xu","sequence":"additional","affiliation":[{"name":"Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Hegg","sequence":"additional","affiliation":[{"name":"University of S\u00e3o Paulo, S\u00e3o Paulo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mafalda","family":"Oliveira","sequence":"additional","affiliation":[{"name":"Vall d\u2019Hebron University Hospital, Vall d\u2019Hebron Institute of Oncology, Vall d\u2019Hebron Barcelona Hospital Campus, Barcelona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Fabi","sequence":"additional","affiliation":[{"name":"Precision Medicine Unit in Senology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Universit\u00e0 Cattolica del Sacro Cuore, Rome"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalya","family":"Vaksman","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Valdez","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinrui","family":"Zhang","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Lai","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara M.","family":"Tolaney","sequence":"additional","affiliation":[{"name":"Dana\u2013Farber Cancer Institute, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"150","reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02309"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02864"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2020.5135"},{"key":"e_1_3_5_5_2","unstructured":"National Cancer Institute. Cancer stat facts: female breast cancer subtypes (https:\/\/seer.cancer.gov\/statfacts\/html\/breast-subtypes.html)."},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202809"},{"key":"e_1_3_5_7_2","unstructured":"National Comprehensive Cancer Network. NCCN guidelines: breast cancer. Version 4.2025 (https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1419)."},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031665"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf034"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2018-0407"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-023-01069-0"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.09.019"},{"key":"e_1_3_5_13_2","unstructured":"Gennari A Martins-Branco D Trapani D Pentheroudakis G Curigliano G Harbeck N. ESMO Metastatic Breast Cancer Living Guideline v1.2. April 2025 (https:\/\/www.esmo.org\/guidelines\/living-guidelines\/esmo-living-guideline-metastatic-breast-cancer)."},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4318"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-0163"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-022-06660-x"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028485"},{"key":"e_1_3_5_18_2","doi-asserted-by":"crossref","unstructured":"Tolaney SM de Azambuja E Kalinsky K et al. Sacituzumab govitecan plus pembrolizumab vs chemotherapy plus pembrolizumab in patients with previously untreated PD-L1 positive advanced or metastatic triple-negative breast cancer: primary results from the randomized phase 3 ASCENT-04\/KEYNOTE-D19 study. Presented at the 2025 American Society of Clinical Oncology Annual Meeting Chicago May 30\u2013June 3 2025.","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA109"},{"key":"e_1_3_5_19_2","unstructured":"BioPharma APAC. Singapore (HSA) approval marks the first in a series of expected approvals of Trodelvy in Asia. February 7 2022 (https:\/\/biopharmaapac.com\/news\/43\/1252\/-singapore-hsa-approval-marks-the-first-in-a-series-of-expected-approvals-of-trodelvy-in-asia.html)."},{"key":"e_1_3_5_20_2","unstructured":"Europeans Medicines Agency. Trodelvy. Summary of product characteristics (https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/trodelvy-epar-product-information_en.pdf)."},{"key":"e_1_3_5_21_2","unstructured":"Chang M. Gilead\u2019s Trodelvy approved for metastatic triple-negative breast cancer in Korea. Korea Biomedical Review. May 9 2023 (https:\/\/www.koreabiomed.com\/news\/articleView.html?idxno=21060)."},{"key":"e_1_3_5_22_2","unstructured":"Pharmaceutical Technology. Everest\u2019s Trodelvy receives approval for breast cancer in China. June 10 2022 (https:\/\/www.pharmaceutical-technology.com\/news\/everest-trodelvy-breast-cancer\/)."},{"key":"e_1_3_5_23_2","unstructured":"TRODELVY (sacituzumab govitecan-hziy) prescribing information. Foster City CA: Gilead Sciences March 2025 (https:\/\/www.gilead.com\/-\/media\/files\/pdfs\/medicines\/oncology\/trodelvy\/trodelvy_pi.pdf)."},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1177\/11782234231203292"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809615"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-0894"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.05.023"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2019.100121"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-1021"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01245-X"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01002"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.01.011"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq195"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.3488"},{"key":"e_1_3_5_36_2","unstructured":"Food and Drug Administration. FDA approves pembrolizumab for high-risk early-stage triple-negative breast cancer. July 2021 (https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pembrolizumab-high-risk-early-stage-triple-negative-breast-cancer)."},{"key":"e_1_3_5_37_2","unstructured":"Merck. European Commission approves KEYTRUDA (pembrolizumab) plus chemotherapy as neoadjuvant treatment then continued as adjuvant monotherapy after surgery for locally advanced or early-stage triple-negative breast cancer at high risk of recurrence. May 24 2022 (https:\/\/www.merck.com\/news\/european-commission-approves-keytruda-pembrolizumab-plus-chemotherapy-as-neoadjuvant-treatment-then-continued-as-adjuvant-monotherapy-after-surgery-for-locally-advanced-or-early-stage-triple\/)."},{"key":"e_1_3_5_38_2","doi-asserted-by":"crossref","unstructured":"Cumaraswamy AA Boyne DJ Henning J-W Ntalla I Brenner D Cheung WY. Canadian (CAN) real-world outcomes for relapsed\/recurrent (R\/R) metastatic triple-negative breast cancer (mTNBC) in the first-line or later (1L+) setting by early or late recurrence status. J Clin Oncol 2023;41(16):Suppl:e18798-e18798 (https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2023.41.16_suppl.e18798).","DOI":"10.1200\/JCO.2023.41.16_suppl.e18798"}],"container-title":["New England Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa2511734","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T22:00:39Z","timestamp":1762984839000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa2511734"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,13]]},"references-count":37,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2025,11,13]]}},"alternative-id":["10.1056\/NEJMoa2511734"],"URL":"https:\/\/doi.org\/10.1056\/nejmoa2511734","relation":{},"ISSN":["0028-4793","1533-4406"],"issn-type":[{"value":"0028-4793","type":"print"},{"value":"1533-4406","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,13]]}}}